Consuming Lacprodan® ISO.WaterShake whey protein isolate before meals can help control blood sugar in gestational diabetes mellitus (GDM), clinical research from Arla Foods Ingredients shows.
GDM occurs when the body is unable to produce enough insulin or use it effectively to maintain normal blood sugar levels during pregnancy. Elevated blood glucose – known as hyperglycaemia – increases the risk of adverse pregnancy outcomes for both babies and mothers. Those with GDM are therefore advised to control their blood glucose levels through measures including diet, weight management and moderate exercise.1,2
Arla Foods Ingredients partnered with Aarhus University and the Steno Diabetes Center in Aarhus to conduct a study on the effects of whey protein on GDM. Published in Diabetes Care, it examines how consuming Lacprodan® ISO.WaterShake before eating influences blood glucose rises in the three hours after meals.2
In the randomised, placebo-controlled, single-blinded crossover trial, 12 women with GDM and 12 with normal glucose tolerance consumed whey protein or a placebo 30 minutes before a 75 g oral glucose tolerance test (OGTT). This is the standard diagnostic tool used to determine whether a pregnant woman has GDM.
The results showed that pre-meal consumption of 20 g Lacprodan® ISO.WaterShake reduced post-meal blood glucose peaks by -1 mmol/L (-18 mg/dl) in those with GDM, and by -0.7 mmol/L (-12.6 mg/dl) in those without.
In home settings, pre-meal doses of 15-30 g of the whey protein consistently lowered post-meal blood glucose levels and reduced fluctuations in women with GDM.
Lise Høj Brunsgaard, Research Scientist at Arla Foods Ingredients, said: “These findings suggest that whey protein may be a safe, effective and promising nutritional strategy to support blood glucose management in women with GDM. For this study, our Lacprodan® ISO.WaterShake whey protein isolate was selected due to its high purity and rapid absorption profile, which made it suitable for investigating its potential role in maternal nutrition during pregnancy.”
Globally, hyperglycaemia in pregnancy is estimated to affect 19.6 % of live births. Of these cases, 79.2 % are due to GDM, accounting for 15.6 % overall, while the remainder result from type 1, type 2 and other forms of diabetes.
The new study builds on previous research showing whey protein’s benefits for glycaemic control in type 2 diabetes.3 Mechanistic studies suggest this effect is linked to enhanced beta-cell function and reduced insulin clearance.4
1International Diabetes Federation ‘Diabetes Atlas: 11th Edition’ (2025)
2Smedegaard, S. et al. ‘Premeal Whey Protein Lowers Postprandial Blood Glucose in Women With Gestational Diabetes Mellitus: A Randomized, Crossover Clinical Trial’ Diabetes Care (2025) https://pubmed.ncbi.nlm.nih.gov/40261798/
3Ashley, K. et al. ‘Identifying Behavioural Determinants to Uptake and Adherence to a Whey Protein Supplement for the Management of Type 2 Diabetes: A Qualitative Interview Study.’ Nutrients (2022) https://pubmed.ncbi.nlm.nih.gov/35276924/
4Smith, K. et al. ‘Pre-Meal Whey Protein Alters Postprandial Insulinemia by Enhancing β-Cell Function and Reducing Insulin Clearance in T2D’ J Clin Endocrinol Metab (2023) https://pubmed.ncbi.nlm.nih.gov/36734166/
Indena’s Quercefit® is an innovative 100 % food-grade delivery system of quercetin based on Phytosome® technology, which optimises quercetin bioavailability (up to 20 times and in the range of a diet rich in vegetables and fruits) with dose linearity. It has been proven to be an effective natural help to manage early stage conditions of COVID-19, in combination with standard care.
Although the emergency due to the pandemic is luckily decreasing at a global level, COVID-19 continues to be the focus for several scientific analysis. Quercetin Phytosome® has been the object of several human studies in the last two years1 – the most recent one issued in January 20232 – which demonstrated that this ingredient, in combination with standard care, when used in early stage of COVID-19, could aid in ameliorating the early conditions and helps keeping the immune system strong, mildening the symptoms and optimising the timing of molecular test conversion from positive to negative.
The most recent study involved a larger group of subjects (100 subjects consisting of 50 people in the quercetin group and 50 ones in the control group) completing the preliminary data anticipated and published in 2021.
Antonella Riva, Head of Product Innovation and Development & LCM of Indena S.p.A, commenting the study “Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomised clinical trial” by Di Pierro et al., explains: “This randomised clinical trial investigated the possible adjuvant effect of an oral quercetin supplementation in mild to moderately symptomatic COVID-19 outpatients. The results revealed that subjects who received quercetin in addition to standard care, cleared the virus better (tested negative for SARS-CoV-2) and had milder symptoms as compared to the people who received the standard care alone. Moreover, participants in the quercetin group also showed statistically significant improvement in the serum levels of inflammatory biomarker LDH. Also the outcomes of our last study then – adds Riva – suggest possible quercetin supplementation effectiveness in the early-stage mild to moderately symptomatic COVID-19 outpatients and may help in optimising the clearance of the SARS-CoV-2 infection, mildening of the symptoms and modulation/control of the host’s inflammatory response. The study also supports the safety of quercetin supplementation in subjects with COVID-19 which has an unpredictable and complex course and hence may be potentially used as an adjuvant alongside routine care in the management of mild to moderate symptoms of COVID-19”.
“We keep devoting resources to clinical research with the aim to get stronger and stronger scientific evidences about Indena’s ingredients. We’re very happy and proud to see such results from our Quercefit® and to give our contribution in helping people’s health which has had to face one of the most serious pandemics in recent years” adds Stefano Togni, Chief Commercial Officer of Indena S.p.A.
Quercetin, a flavonol not naturally present in the human body, is the most abundant polyphenol in fruits and vegetable and is widely used as a dietary supplement to boost the immune system and in general to promote a healthy condition. Quercetin is characterised by crucial pharmacological properties including, antioxidant and immune-protective effects, which allows it to be a potential candidate to support all unpleasant conditions.
1Di Pierro et al., Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study, International Journal of General Medicine 2021:14 2359–2366. https://www.dovepress.com/possible-therapeutic-effects-of-adjuvant-quercetin-supplementation-aga-peer-reviewed-fulltext-article- IJGM https://pubmed.ncbi.nlm.nih.gov/34135619/
Di Pierro et al., Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial, International Journal of General Medicine 2021:14 2807–2816. https://www.dovepress.com/potential-clinical-benefits-of-quercetin-in-the-early-stage-of-covid-1-peer-reviewed-fulltext-article-IJGM Rondanelli et al., Promising Effects of 3-Month Period of Quercetin Phytosome® Supplementation in the Prevention of Symptomatic COVID-19 Disease in Healthcare Workers: A Pilot Study 2022: 12 66 https://pubmed.ncbi.nlm.nih.gov/35054459/
2Di Pierro et al., Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial, Front. Pharmacol. 13:1096853. doi: 10.3389/fphar.2022.1096853
